Issue link: https://beckershealthcare.uberflip.com/i/1335763
35 DEVICES & IMPLANTS OrthoPediatrics expands into the UK By Carly Behm O rthoPediatrics is expanding into the Unit- ed Kingdom commercial market with the approval and launch of two surgical systems, according to a Dec. 21 news release. e company received U.K. regulatory clearance for its pediatric nailing platform for femoral fractures and ini- tiated its ApiFix system for posterior dynamic deformity correction system, the release said. e femoral surgical platform uses an intramedullary nailing system with distinct implants for children and adolescents, the release said. e ApiFix system is ap- proved for use in children with spine curves and early onset scoliosis. "Our continued international expansion represents our commitment to being the end-to-end provider of pedi- atric orthopedics solutions around the globe," OrthoPe- diatrics president Dave Bailey said in the release. "Our ability to provide innovative technology to pediatric or- thopedic surgeons in their home markets is something I am very proud of, and as we head into the new year, we look forward to expanding our global footprint." n Spinal biologics market to hit $2.3B by 2027: 5 notes By Alan Condon T he FDA has awarded Carlsmed's aprevo device its break- through device designation, which will expedite the time it takes to reach clinical trials. The global spinal biologics industry is projected to reach $2.3 billion by 2027, growing at a compound annual growth rate of 2.8 percent, according to ReportLinker.com. Five notes: 1. The spinal biologics market is estimated at $1.9 billion for 2020, with the U.S. accounting for $504 million. 2. The revised report reduced previously communicated projections due to the economic implications caused by the COVID-19 pandem- ic. 3. The bone graft market segment is expected to rise at a CAGR of 2.6 percent and reach $1.4 billion by 2027. 4. China is anticipated to see a 5.2 percent CAGR in the spinal biolog- ics market, hitting $457.7 million by the end of the forecast period. 5. Japan, Canada and Germany are highlighted as noteworthy mar- ket competitors. n 866-948-7673 • nationalASCbilling.com THE ASC REVENUE CYCLE. It's all we do. It's all we think about. And it shows. UNPARALLELED EXPERTISE | PROPRIETARY PROCESSES | INTELLIGENT ANALYTICS | STRATEGIC VISION | EXCEPTIONAL RESULTS | THE BUSINESS OF Powering Profitability